Allos Therapeutics (ALTH) Updates Phase 2 PROPEL Study At ASCO
More News related to ALTH
- Allos Therapeutics Reports New Analyses of Data from Pivotal PROPEL Trial of FOLOTYN(TM) at 51st ASH Annual Meeting
- Allos Therapeutics (ALTH) Collaborates with Idis to Manage FOLOTYN Outside U.S.
- Allos Therapeutics Announces an Agreement with Idis for a Named Patient Program for FOLOTYN(TM) (pralatrexate injection)
- Allos Therapeutics (ALTH) Launches COMPLETE Registery for PTCL Patients
- Allos Therapeutics to Launch Global Registry for Patients with Peripheral T-Cell Lymphoma at the American Society of Hematology Annual Meeting
More News related to FDA
- After Month's Of Gains, Gold Gives A Little Back Today (GDX, GLD, DGL, More)
- Office Supplies Cos. Up On Jobs Report: OMX, SPLS, ODP
- Synovus Financial (SNV) Running Up on FBR Upgrade
- Staffing Service Stocks Higher As Job Creation Now In Sight: MAN, MWW, RHI, KELYA, TBI, SFN, ASGN
- Novartis for Alcon (ACL)? Novartis Says "No" But Market Says "Yes"
At ASCO, Allos Therapeutics, Inc. (Nasdaq: ALTH) reported updated data from the Company's pivotal Phase 2 PROPEL study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma.
The overall response rate for pralatrexate as evaluated by central independent oncology review using International Workshop Criteria (IWC) was 28% (30 of 109 evaluable patients) with a median duration of response of 9.4 months, or 287 days. Of the 30 patients who responded to pralatraxate, 21 patients (70%) did so after cycle one of therapy. Median overall survival was 14.7 months, with 57% of responders surviving 12 months or more. The most common Grade 3/4 adverse events were thrombocytopenia, mucositis, neutropenia, and anemia, which were manageable.
More from Release
Related Categories
FDAStocks Mentioned
+0.16Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
